UK medical cannabis prescribing remains below 1 percent. This article examines the scientific and regulatory barriers behind this gap, including trial limitations, real-world evidence, ECS variability, and systemic challenges. A must-read for anyone interested in cannabinoid science, medical innovation, and the future of UK healthcare.